Outcomes after the Ross procedure with pulmonary autograft reinforcement by reimplantation.
CT, computed tomography
Ross procedure
aortic valve repair
congenital heart disease
Journal
JTCVS techniques
ISSN: 2666-2507
Titre abrégé: JTCVS Tech
Pays: United States
ID NLM: 101768546
Informations de publication
Date de publication:
Feb 2023
Feb 2023
Historique:
received:
14
06
2022
revised:
31
10
2022
accepted:
14
11
2022
entrez:
23
2
2023
pubmed:
24
2
2023
medline:
24
2
2023
Statut:
epublish
Résumé
Pulmonary autograft reinforcement to prevent dilatation and subsequent neo-aortic valve regurgitation has been reported; however, data on long-term function of the neo-aortic valve after this modified Ross procedure are lacking. Our objective here was to assess long-term outcomes of the modified Ross procedure with autograft reinforcement using the reimplantation technique. The outcomes of 61 consecutive patients managed using the Dacron-conduit reinforced Ross procedure between 2009 and 2021 were reviewed. Most patients had a unicuspid or bicuspid aortic valve (n = 52; 85%), predominant aortic valve regurgitation (n = 42; 77%), and >30 mm dilatation of the ascending aorta (n = 33; 54%). A prior aortic valve procedure was noted in 47 patients (77%) patients, including 38 (62%) with surgical repair and 9 (15%) with balloon dilatation. The pulmonary autograft was reimplanted within a Dacron conduit with a median diameter of 25.6 mm (range, 20-30 mm) using the David valve-sparing aortic root replacement technique. All patients survived. The median age at surgery was 16.8 years (range, 6-38 years). Neo-aortic valve replacement was required in 3 patients (4.9%; 95% CI, 0.34%- 12.7%) because of infective endocarditis, left ventricular false aneurysm, and leaflet perforation, respectively; the repeat procedure was done early in 2 of these patients (2 of 61; 3%). Six patients required right ventricular outflow conduit replacement, 5 by surgery and 1 percutaneously. The median duration of follow-up was 90 months (range, 10-124 months). The 5- and 10-year rates of reintervention-free survival were 84.3% (95% CI, 74%-95%) and 81.6% (95% CI, 72%-93%), respectively, and 5-year survival without aortic reintervention was 94.5% (95% CI, 88%-100%), with little change at 10 years. No patients experienced deterioration of initial neo-aortic valve function (ie, regurgitation or stenosis). Autograft reinforcement using the reimplantation technique allowed expansion of Ross procedure indications to all patients requiring aortic valve replacement and prevented neo-aortic root dilatation. Failures were uncommon. Long-term follow-up data showed stable neo-aortic valve function.
Sections du résumé
Background
UNASSIGNED
Pulmonary autograft reinforcement to prevent dilatation and subsequent neo-aortic valve regurgitation has been reported; however, data on long-term function of the neo-aortic valve after this modified Ross procedure are lacking. Our objective here was to assess long-term outcomes of the modified Ross procedure with autograft reinforcement using the reimplantation technique.
Patients
UNASSIGNED
The outcomes of 61 consecutive patients managed using the Dacron-conduit reinforced Ross procedure between 2009 and 2021 were reviewed. Most patients had a unicuspid or bicuspid aortic valve (n = 52; 85%), predominant aortic valve regurgitation (n = 42; 77%), and >30 mm dilatation of the ascending aorta (n = 33; 54%). A prior aortic valve procedure was noted in 47 patients (77%) patients, including 38 (62%) with surgical repair and 9 (15%) with balloon dilatation. The pulmonary autograft was reimplanted within a Dacron conduit with a median diameter of 25.6 mm (range, 20-30 mm) using the David valve-sparing aortic root replacement technique.
Results
UNASSIGNED
All patients survived. The median age at surgery was 16.8 years (range, 6-38 years). Neo-aortic valve replacement was required in 3 patients (4.9%; 95% CI, 0.34%- 12.7%) because of infective endocarditis, left ventricular false aneurysm, and leaflet perforation, respectively; the repeat procedure was done early in 2 of these patients (2 of 61; 3%). Six patients required right ventricular outflow conduit replacement, 5 by surgery and 1 percutaneously. The median duration of follow-up was 90 months (range, 10-124 months). The 5- and 10-year rates of reintervention-free survival were 84.3% (95% CI, 74%-95%) and 81.6% (95% CI, 72%-93%), respectively, and 5-year survival without aortic reintervention was 94.5% (95% CI, 88%-100%), with little change at 10 years. No patients experienced deterioration of initial neo-aortic valve function (ie, regurgitation or stenosis).
Conclusions
UNASSIGNED
Autograft reinforcement using the reimplantation technique allowed expansion of Ross procedure indications to all patients requiring aortic valve replacement and prevented neo-aortic root dilatation. Failures were uncommon. Long-term follow-up data showed stable neo-aortic valve function.
Identifiants
pubmed: 36820346
doi: 10.1016/j.xjtc.2022.11.016
pii: S2666-2507(22)00596-X
pmc: PMC9938391
doi:
Types de publication
Journal Article
Langues
eng
Pagination
121-128Informations de copyright
© 2023 The Authors.
Références
Rev Port Cardiol (Engl Ed). 2019 May;38(5):315-321
pubmed: 31221488
J Thorac Cardiovasc Surg. 2008 Sep;136(3):623-30, 630.e1-5
pubmed: 18805263
Lancet. 1967 Nov 4;2(7523):956-8
pubmed: 4167516
Ann Thorac Surg. 2009 Oct;88(4):e34-6
pubmed: 19766774
Eur J Cardiothorac Surg. 2010 Nov;38(5):547-55
pubmed: 20409726
J Thorac Cardiovasc Surg. 2010 Jun;139(6):1420-3
pubmed: 20381090
J Thorac Cardiovasc Surg. 2000 Jan;119(1):4-9
pubmed: 10612754
Eur J Cardiothorac Surg. 2007 Jan;31(1):127-8
pubmed: 17092738
Ann Thorac Surg. 1999 Mar;67(3):745-50
pubmed: 10215221
Eur J Cardiothorac Surg. 2019 Nov 1;56(5):959-967
pubmed: 30938412
Circulation. 2006 Jul 4;114(1 Suppl):I504-11
pubmed: 16820628
J Am Coll Cardiol. 2020 Sep 29;76(13):1564-1573
pubmed: 32972534
J Thorac Cardiovasc Surg. 2012 Oct;144(4):813-21; discussion 821-3
pubmed: 22883549
J Thorac Cardiovasc Surg. 2019 Aug;158(2):392-403
pubmed: 30745047
J Thorac Cardiovasc Surg. 2001 Jul;122(1):147-53
pubmed: 11436048
Eur J Cardiothorac Surg. 2021 Nov 2;60(5):1122-1123
pubmed: 34329399
J Heart Valve Dis. 1994 Jul;3(4):365-70
pubmed: 7952308
J Thorac Dis. 2020 Mar;12(3):1219-1223
pubmed: 32274203
J Thorac Cardiovasc Surg. 1994 Feb;107(2):367-73
pubmed: 8302055
Circulation. 2009 Jan 20;119(2):222-8
pubmed: 19118260
Semin Thorac Cardiovasc Surg. 2020 Autumn;32(3):498-504
pubmed: 31863831
J Am Coll Cardiol. 2018 Mar 27;71(12):1337-1344
pubmed: 29566818
J Thorac Cardiovasc Surg. 1997 Apr;113(4):667-74
pubmed: 9104975
Ann Thorac Surg. 1994 Jun;57(6):1387-93; discussion 1393-4
pubmed: 8010778
J Thorac Cardiovasc Surg. 2008 Aug;136(2):472-5
pubmed: 18692659
Ann Thorac Surg. 2012 Feb;93(2):598-604; discussion 605
pubmed: 21983074
J Am Coll Cardiol. 2021 Mar 23;77(11):1412-1422
pubmed: 33736823
N Engl J Med. 1994 Jan 6;330(1):1-6
pubmed: 8259138
Semin Thorac Cardiovasc Surg. 2011 Summer;23(2):115-23
pubmed: 22041040
Eur J Cardiothorac Surg. 2010 May;37(5):1002-7
pubmed: 20138780
J Thorac Cardiovasc Surg. 2000 Feb;119(2):210-20
pubmed: 10649195